The estimated Net Worth of Joan Elizabeth Miller is at least $18.6 million dollars as of 24 February 2012. Joan Miller owns over 15,561 units of Quest Diagnostics stock worth over $13,656,705 and over the last 17 years Joan sold DGX stock worth over $4,900,177.
Joan has made over 8 trades of the Quest Diagnostics stock since 2011, according to the Form 4 filled with the SEC. Most recently Joan exercised 15,561 units of DGX stock worth $880,753 on 24 February 2012.
The largest trade Joan's ever made was selling 42,365 units of Quest Diagnostics stock on 12 May 2011 worth over $2,432,175. On average, Joan trades about 4,142 units every 9 days since 2008. As of 24 February 2012 Joan still owns at least 88,934 units of Quest Diagnostics stock.
You can see the complete history of Joan Miller stock trades at the bottom of the page.
Joan's mailing address filed with the SEC is C/O QUEST DIAGNOSTICS INCORPORATED, 3 GIRALDA FARMS, MADISON, NJ, 07940.
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty et Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: